Bone morphogenetic protein 7 in the treatment of congenital pseudarthrosis of the tibia.

Human Bone Morphogenetic Protein-7 (rhBMP-7) A Report of Five Treatment of Congenital Pseudarthrosis of the Tibia with Recombinant

Combined treatment of congenital pseudarthrosis of the tibia, including recombinant human bone morphogenetic protein-2: a case series.

The use of recombinant human bone morphogenetic protein-2 (rhBMP-2) for the treatment of congenital pseudarthrosis of the tibia has been investigated in only one previous study, with promising results. The aim of this study was to determine whether rhBMP-2 might improve the outcome of this disorder. We reviewed the medical records of five patients with a mean age of 7.4 years (2.3 to 21) with c...

Wrapping grafting for congenital pseudarthrosis of the tibia

OBJECTIVE Treatment of congenital pseudarthrosis of the tibia (CPT) remains a challenge. The autogenic iliac bone graft is important consistent of treatment for CPT. The purpose of this study was to investigate the role of wrapping autogenic iliac bone graft in improvement of the curing opportunities of CPT. METHODS We combined Ilizarov fixator with intramedullary rodding of the tibia and wra...

Treatment of congenital pseudarthrosis of the tibia with native bovine BMP: a case report.

Bone morphogenetic proteins (BMP) have been shown to induce bone formation and union in long bone defects and nonunions. We report a case of congenital pseudarthrosis of the tibia treated with a composite implant consisting of a biocoral frame, collagen carrier, and native bovine BMP extract. A six-year-old boy had persisting congenital proximal tibial pseudarthrosis despite six prior operation...

Einsatz der Bone morphogenetic Proteins (BMPs) zur Behandlung von Pseudarthrosen – Effizienz und Therapieversagen Use of Bone Morphogenetic Proteins (BMPs) for the Treatment of Pseudarthroses – Efficiency and Therapy Failure

In der Therapie von Pseudarthrosen der proximalen Tibia kommen seit einigen Jahren die humanen rekombinanten „bone morphogenetic proteins“ (BMP-2 und BMP-7) zum Einsatz. Trotz limitiertem und spezifischem Einsatz als lokale Mediatoren der Knochenheilung können bisher keine Aussagen über den jeweiligen Erfolg der Therapie im Voraus getroffen werden. Die Regelmechanismen zeigen sich als wesentlic...